Cancer Diagnosis and Therapy
A randomised, double-blind, placebo-controlled trial of photodynamic therapy using 5-aminolaevulinic acid for the treatment of cervical intraepithelial neoplasia
Article first published online: 6 DEC 2002
Copyright © 2002 Wiley-Liss, Inc.
International Journal of Cancer
Volume 103, Issue 6, pages 829–832, 1 March 2003
How to Cite
Barnett, A. A., Haller, J. C., Cairnduff, F., Lane, G., Brown, S. B. and Roberts, D. J.H. (2003), A randomised, double-blind, placebo-controlled trial of photodynamic therapy using 5-aminolaevulinic acid for the treatment of cervical intraepithelial neoplasia. Int. J. Cancer, 103: 829–832. doi: 10.1002/ijc.10888
- Issue published online: 3 JAN 2003
- Article first published online: 6 DEC 2002
- Manuscript Accepted: 7 OCT 2002
- Manuscript Revised: 18 SEP 2002
- Manuscript Received: 12 JUL 2002
- Yorkshire Cancer Research
Photodynamic therapy (PDT) using topical 5-aminolaevulinic acid (ALA) has been used to treat histologically confirmed cervical intraepithelial neoplasia (CIN-I and -I/II) in a randomised, double-blind, placebo-controlled protocol. Fluorescence microscopy revealed that topical application of 3% ALA in Intrasite Gel® to the cervix for 3 hr resulted in the accumulation of protoporphyrin IX in the cervical epithelium. Treatment of CIN with ALA-PDT was well tolerated, with only 3/12 patients in the PDT arm (0/13 in the placebo arm) reporting any discomfort during illumination. Histologic examination of the treated tissue following loop excision 3 months post-PDT indicated that 33% of patients had no evidence of CIN, 42% had no change in the grade of their disease, whilst 25% exhibited an apparent progression of disease. In the control group, the respective figures were 31%, 38% and 31%. There was no significant difference in response between the groups receiving ALA-PDT and those receiving placebo treatment. © 2002 Wiley-Liss, Inc.